{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:05:38Z","timestamp":1772294738774,"version":"3.50.1"},"reference-count":46,"publisher":"The Japanese Society for Medical Mycology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Mycology Journal"],"published-print":{"date-parts":[[2024,7,31]]},"DOI":"10.3314\/mmj.24.005","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T22:15:17Z","timestamp":1725056117000},"page":"59-65","source":"Crossref","is-referenced-by-count":3,"title":["Optimized Antifungal Therapy for Chronic Pulmonary Aspergillosis"],"prefix":"10.3314","volume":"65","author":[{"given":"Yusuke","family":"Yagi","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital"},{"name":"Department of Infection Prevention and Control, Kochi Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Department of Infection Prevention and Control, Kochi Medical School Hospital"},{"name":"Department of Clinical Infectious Diseases, Kochi Medical School, Kochi University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kochi Medical School Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1842","reference":[{"key":"1","unstructured":"1) Committee for the development of guidelines for deep mycosis: Guidelines for diagnosis and treatment of deep mycosis 2014. Kyowa Kikaku, Tokyo, 2014; p.215&ndash;61. (in Japanese)"},{"key":"2","unstructured":"2) Committee for the Preparation of Guidelines for the Diagnosis and Treatment of Aspergillosis, The Japanese Society for Medical Mycology: Guidelines for the Diagnosis and Treatment of Aspergillosis 2015. p.127, The Japanese Society for Medical Mycology, Tokyo, 2015. (in Japanese)"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63: e1&ndash;60, 2016.","DOI":"10.1093\/cid\/ciw326"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al: Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 47: 45&ndash;68, 2016.","DOI":"10.1183\/13993003.00583-2015"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Koyama K, Ohshima N, Suzuki J, Kawashima M, Takeda K, Ando T, et al: Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles. J Infect Chemother 20: 375&ndash;9, 2014.","DOI":"10.1016\/j.jiac.2014.02.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sehgal IS, Dhooria S, Muthu V, Prasad KT, Aggarwal AN, Chakrabarti A, et al: Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomized controlled trial in India. Lancet Infect Dis 22: 1052&ndash;61, 2022.","DOI":"10.1016\/S1473-3099(22)00057-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34: 563&ndash;71, 2002.","DOI":"10.1086\/324620"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Takeda K, Suzuki J, Watanabe A, Arai T, Koiwa T, Shinfuku K, et al: High detection rate of azole-resistant <i>Aspergillus fumigatus<\/i> after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance. Med Mycol 59: 327&ndash;34, 2021.","DOI":"10.1093\/mmy\/myaa052"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) van Wanrooy MJP, Rodgers MGG, Span LFR, Zijlstra JG, Uges DRA, Kosterink JGW, et al: Voriconazole therapeutic drug monitoring practices in intensive care. Ther Drug Monit 38: 313&ndash;8, 2016.","DOI":"10.1097\/FTD.0000000000000284"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ruiz J, Gordon M, Villarreal E, Peruccioni M, Marqu\u00e9s MR, Poveda-Andr\u00e9s JL, et al: Impact of voriconazole plasma concentrations on treatment response in critically ill patients. J Clin Pharm Ther 44: 572&ndash;8, 2019.","DOI":"10.1111\/jcpt.12817"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, et al; Japan Chronic Pulmonary Aspergillosis Study Group: Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 61: 410&ndash;8, 2010.","DOI":"10.1016\/j.jinf.2010.08.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K, et al: A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 32: 387&ndash;97, 2013.","DOI":"10.1007\/s10096-012-1754-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Tomioka H, Kaneda T, Kida Y, Kaneko M, Fujii H, Hayashi M, et al: An open, noncomparative multicenter study of the efficacy and safety of itraconazole injections and high dose capsules in chronic pulmonary aspergillosis. Kansenshogaku Zasshi 35: 644&ndash;51, 2011. [Article in Japanese]","DOI":"10.11150\/kansenshogakuzasshi.85.644"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Schweer KE, Bangard C, Hekmat K, Cornely OA: Chronic pulmonary aspergillosis. Mycoses 57: 257&ndash;70, 2014.","DOI":"10.1111\/myc.12152"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ullmann AJ, Aguado JM, Ar\u0131kan-Akda\u011fl\u0131 S, Denning DW, Groll AH, Lagrou K, et al: Diagnosis and management of <i>Aspergillus<\/i> diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24 (Suppl 1): e1&ndash;38, 2018.","DOI":"10.1016\/j.cmi.2018.01.002"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Van Braeckel E, Page I, Davidsen JR, Laursen CB, Agarwal R, Alastruey-Izquierdo A, et al: Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. Eur Respir J 59: 2102950, 2022.","DOI":"10.1183\/13993003.02950-2021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sprute R, Van Braeckel E, Flick H, Hoenigl M, Kosmidis C, Agarwal R, et al: EQUAL CPA Score 2022: a tool to measure guideline adherence for chronic pulmonary aspergillosis. J Antimicrob Chemother 78: 225-31, 2022.","DOI":"10.1093\/jac\/dkac378"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Cornely OA, K\u00f6ehler P, Arenz D, Mellinghoff SC: EQUAL Aspergillosis Score 2018: an ECMM score derived from current guidelines to measure QUALity of the clinical management of invasive pulmonary aspergillosis. Mycoses 61: 833&ndash;6, 2018.","DOI":"10.1111\/myc.12820"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kubota T, Chiba K, Ishizaki T: Genotyping of S-mephenytoin 4\u2019-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 60: 661&ndash;6, 1996.","DOI":"10.1016\/S0009-9236(96)90214-3"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Siopi M, Mavridou E, Mouton JW, Verweij PE, Zerva L, Meletiadis J: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus<\/i> in an <i>in vitro<\/i> pharmacokinetic\/pharmacodynamic model. J Antimicrob Chemother 69: 1611&ndash;9, 2014.","DOI":"10.1093\/jac\/dku023"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Kuo IF, Ensom MHH: Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. Can J Hosp Pharm 62: 469&ndash;82, 2009.","DOI":"10.4212\/cjhp.v62i6.845"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hamada Y, Seto Y, Yago K, Kuroyama M: Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother 18: 501&ndash;7, 2012.","DOI":"10.1007\/s10156-011-0363-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ebihara F, Hamada Y, Kato H, Maruyama T, Kimura T: Importance and reality of TDM for antibiotics not covered by insurance in Japan. Int J Environ Res Public Health 19: 2516, 2022.","DOI":"10.3390\/ijerph19052516"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hamada Y, Ueda T, Miyazaki Y, Nakajima K, Fukunaga K, Miyazaki T, et al: Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: a multicentre study conducted in Japan. Mycoses 63: 779&ndash;86, 2020.","DOI":"10.1111\/myc.13129"},{"key":"25","unstructured":"25) Hanai Y, Matsuo K, Uekusa S, Kosugi T, Yoshio T, Nishizawa K: Benefits of measuring plasma voriconazole concentrations in hospitals. Jpn J Chemother 67: 556&ndash;66, 2019. [Article in Japanese]"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kato H, Umemura T, Hagihara M, Shiota A, Asai N, Hamada Y, et al: Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: a multicentre retrospective study. Br J Clin Pharmacol 90: 1222&ndash;30, 2024.","DOI":"10.1111\/bcp.16004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ebihara F, Maruyama T, Kikuchi K, Kimura T, Hamada Y: Antifungal stewardship task shifting required of pharmacists. Med Mycol J 63: 109&ndash;17, 2022.","DOI":"10.3314\/mmj.22.003"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Hamada Y, Tokimatsu I, Mikamo H, Kimura M, Seki M, Takakura S, et al: Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 19: 381&ndash;92, 2013.","DOI":"10.1007\/s10156-013-0607-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hanai Y, Hamada Y, Kimura T, Matsumoto K, Takahashi Y, Fujii S, et al: Favorable effects of voriconazole trough concentrations exceeding 1\u00b5g\/mL on treatment success and all-cause mortality: a systematic review and 310 meta-analysis. J Fungi (Basel) 7: 306, 2021.","DOI":"10.3390\/jof7040306"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Styczy\u0144ski J, van der Velden W, Fox CP, Engelhard D, de la C\u00e1mara R, Cordonnier C, et al: Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 101: 803&ndash;11, 2016.","DOI":"10.3324\/haematol.2016.144428"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope W: Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 69: 1162&ndash;76, 2014.","DOI":"10.1093\/jac\/dkt508"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kosmidis C, Otu A, Moore CB, Richardson MD, Rautemaa-Richardson R: Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis. Antimicrob Agents Chemother 65: e01511&ndash;20, 2020.","DOI":"10.1128\/AAC.01511-20"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Scodavolpe S, Quaranta S, Lacarelle B, Solas C: Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization. Ann Biol Clin (Paris) 72: 391&ndash;404, 2014.","DOI":"10.1684\/abc.2014.0968"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Chau M, Kong DCM, van Hal SJ, Urbancic K, Trubiano JA, Cassumbhoy M, et al: Consensus guidelines for optimizing antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J 44: 1364&ndash;88, 2014.","DOI":"10.1111\/imj.12600"},{"key":"35","unstructured":"35) Clinical and Laboratory Standards Institute: <i>In<\/i> M61 Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi (2nd ed.), p. 28, CLSI, Wayne, Pennsylvania, USA, 2020."},{"key":"36","unstructured":"36) The European Committee on Antimicrobial Susceptibility Testing: Overview of antifungal ECOFFs and clinical breakpoints for yeasts, moulds and dermatophytes using the EUCAST E.Def 7.3, E.Def 9.4 and E.Def 11.0 procedures Version 3.0 [Internet]. 2022 Jan [cited 2022 Dec 1]; Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Clinical_breakpoins\/AFST_EUCAST_BP_ECOFF_v3.0_18_01_22.pdf"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T, Hosogaya N, et al: Correlation between triazole treatment history and susceptibility in clinically isolated <i>Aspergillus fumigatus<\/i>. Antimicrob Agents Chemother 56: 4870&ndash;5, 2012.","DOI":"10.1128\/AAC.00514-12"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Arastehfar A, Carvalho A, Houbraken J, Lombardi L, Garcia-Rubio R, Jenks JD, et al: <i>Aspergillus fumigatus<\/i> and aspergillosis: from basics to clinics. Stud Mycol 100: 100115, 2021.","DOI":"10.1016\/j.simyco.2021.100115"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kikuchi K, Watanabe A, It\u00f4 J, Oku Y, Wuren T, Taguchi H, et al: Antifungal susceptibility of <i>Aspergillus fumigatus<\/i> clinical isolates collected from various areas in Japan. J Infect Chemother 20: 336&ndash;8, 2014.","DOI":"10.1016\/j.jiac.2014.01.003"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Ito Y, Takazono T, Koga S, Nakano Y, Ashizawa N, Hirayama T, et al: Clinical and experimental phenotype of azole-resistant <i>Aspergillus fumigatus<\/i> with a HapE splice site mutation: a case report. BMC Infect Dis 21: 573, 2021.","DOI":"10.1186\/s12879-021-06279-1"},{"key":"41","unstructured":"41) Azuma J, Nakahara K, Kagayama A, Okuma T, Kawamura A, Mukai T: Pharmacokinetic study of micafungin. Jpn J Chemother 50 (Suppl 1): 155&ndash;84, 2002. [Article in Japanese]"},{"key":"42","unstructured":"42) Ueno R, Ikeda H, Ogawa M, Higashitsuji Y, Hattori J, Yoshinari T, et al: <i>In vitro<\/i> susceptibility study of clinical isolates of <i>Candida<\/i> and <i>Aspergillus<\/i> species to caspofungin (Additional Report): a post-marketing surveillance report. Jpn J Chemother 67: 651&ndash;9, 2019. [Article in Japanese]"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Barrett J, Vardulaki K, Conlon CP, Cooke J, Daza-Ramirez P, Evans EG, et al: A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 25: 1295&ndash;320, 2003.","DOI":"10.1016\/S0149-2918(03)80125-X"},{"key":"44","unstructured":"44) Kohno S, Kobayashi H, Masaoka T, Urabe A, Kanamaru A, Niki Y, et al: Evaluation of efficacy and safety of liposomal amphotericin B (L-AMB) in deep-seated fungal infection. Jpn J Chemother 61: 347&ndash;68, 2013. [Article in Japanese]"},{"key":"45","unstructured":"45) Fujita M, Hirano R, Matsumoto T, Watanabe K: Pilot study of intermittent administration of liposomal amphotericin B for chronic pulmonary aspergillosis. Jpn J Antibiot 67: 205&ndash;10, 2014. [Article in Japanese]"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Takeda T, Itano H, Kakehashi R, Fukita S, Saitoh M, Takeda S: Direct transbronchial administration of liposomal amphotericin B into a pulmonary aspergilloma. Respir Med Case Rep 11: 7&ndash;11, 2014.","DOI":"10.1016\/j.rmcr.2013.12.003"}],"container-title":["Medical Mycology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/65\/3\/65_59\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T04:51:22Z","timestamp":1725079882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/mmj\/65\/3\/65_59\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3314\/mmj.24.005","relation":{},"ISSN":["2185-6486","2186-165X"],"issn-type":[{"value":"2185-6486","type":"print"},{"value":"2186-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]}}}